The estrogen and progesterone receptors - setting the scene for pharmacodiagnostics

Molecular Diagnostics: The Key Driver in Personalized Cancer Medicine

Volumn , Issue , 2010, Pages 21-42

  Cheung, Kwok Leung ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859211174     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814241458     Document Type: Chapter

References (67)

1. O'Malley B. Thirty years of steroid hormone action: personal recollections of an investigator. Steroids 1995;60:490-8.
2. Jensen E, Greene G, Closs L, DeSombre E, Nadji M. Receptors reconsidered: a 20-year perspective. Recent Progress in Hormone Research 1982;38:1-40.
3. Sanders S. The in vitro uptake of oestradiol in biopsies from 25 breast cancer patients. Acta Pathologica et Microbiologica Scandinavica 1968;74:301-2.
4. Johansson H, Terenius L, Thoren L. The binding of estradiol-17beta to human breast cancers and other tissues in vitro. Cancer Research 1970;30:692-8.
5. Jensen E, Block G, Smith S, Kyser K, DeSombre E. Estrogen receptors and breast cancer response to adrenalectomy. NCI Monographs 1971;34:55-67.
6. Howell T. New endocrine agents. Cancer Treat Rev 1997;23:S49-57.
7. Speirs V, Malone C, Walton D, Kerin M, Atkin S. Increased expression of estrogen receptor ß mRNA in tamoxifen-resistant breast cancer patients. Cancer Research 1999;59:5421-5424.
8. Wen D, You-Feng X, Mais D, Goldman M, McDonnell D. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Molecular Cellular Biology 1994;14:8356-64.
9. McCormack O, Harrison M, Kerin M, McCann A. Role of the Progesterone Receptor (PR) and the PR Isoforms in Breast Cancer. Critical Reviews in Oncogenetics 2007;13:283-302.
10. McCormack O, Chung W, Fitzpatrick P, Cooke F, Flynn B, Harrison M, et al. Progesterone receptor B promoter hypermethylation in sporadic breast cancer. Breast Cancer Research and Treatment 2007.
11. Robertson J, Bates K, Pearson D, Blamey R, Nicholson R. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. British Journal of Cancer 1992;65:727-30.
12. Saccani Jotti G, Johnston S, Salter J, Detre S, Dowsett M. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. Journal of Clinical Pathology 1994;47:900-5.
13. Fisher B, Wickerham DL, Brown A, Redmond C, et al. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. Journal of Clinical Oncology 1983;1:108-17.
14. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegro J, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. Journal of Clinical Oncology 1983;1:93-107.
15. Howell A, Barnes D, Harland R, et al. Steroid-hormone receptors in survival after first relapse in breast cancer. Lancet 1984;1:588-591.
16. Harvey J, Clark G, Osborne C, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 1999;115:44-58.
17. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, et al. Estrogenand progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. Journal of Clinical Oncology 2008;26:2473-81.
18. Hodi Z, Chakrabarti J, Lee A, Ronan J, Elston C, Cheung K, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsies of invasive carcinomas of the breast. Journal of Clinical Pathology 2007;60:299-302.
19. Jacobs T, Siziopikou K, Prioleau J, Raza S, Baum J, Hayes D, et al. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Modern Pathology 1998;11:259-63.
20. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 2004;351:2817-26.
21. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet 1896;2:104-107.
22. Lerner LJ, Holthaus JF, Thompson CR. A nonsteroidal estrogen antagnoist 1-(p-2- diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 1958;63:295-318.
23. Harper MJK, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature (London) 1966;212:87.
24. Harper MJK, Walpole AL. A new derivative of triphenylethylene: effect onn implantation and mode of action in rats. Journal of Reproduction and Fertility 1967;13:101-19.
25. Harper MJK, Walpole AL. Mode of action of ICI 46,474 in preventing implantation in rats. Journal of Endocrinology 1967;37:83-92.
26. Cole M, Jones C, Todd I. A new antioestrogenic agent in late breast cancer. An early appraisal of ICI 46,474. British Journal of Cancer 1971;25:270-275.
27. Cheung K. Endocrine therapy for breast cancer - An overview. Breast 2007;16: 327-43.
28. Cheung K, Howell A, Robertson J. Preoperative endocrine therapy for breast cancer. Endocrine-related Cancer 2000;7:131-141.
29. Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. New England Journal of Medicine 1981;305:1.
30. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
31. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a metaanalysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23.
32. Cummings S, Eckert S, Krueger K, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197.
33. Cheung K, Robertson J. Fulvestrant. Expert Opinion in Investigational Drugs 2002;11:303-8.
34. Howell A, Robertson J, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg U, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 2002;20:3396-3403.
35. Osborne C, Pippen J, Jones S, Parker L, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 2002;20:3386-3395.
36. Robertson J, Osborne C, Howell A, Jones S, Mauriac L, Ellis M, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238.
37. Lonning P, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg P, Mickiewicz E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 2000;18: 2234-2244.
38. Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005;69:471-7.
39. Bonneterre J, Thurlimann D, Robertson Jea. Anastrozole versus tamoxifen as firstline therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. Journal of Clinical Oncology 2000;18:3748-3757.
40. Nabholtz J, Buzdar A, Pollak M, et al. Arimidex Study Group: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology 2000;18:3758-3767.
41. Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormonedependent advanced breast cancer: a prospective, randomized, phase III study. American Journal of Clinical Oncology 2003;26:317-322.
42. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 2001;19:2596-2606.
43. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, et al. European Organisation for the Research and Treatment of Cancer (EORTC) - Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology 2003;14:1391-1398.
44. Eirmann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
45. Arimidex T, Alone or in Combination (ATAC) Trialists' Group, Forbes J, Cuzick J, Buzdar A, Howell A, Tobias J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 2008;9:45-53.
46. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates A, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 2005;353:2747-57.
47. Coates A, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes J, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 2007;25:486-92.
48. Coombes R, Hall E, Gibson L, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 2004;350:1081-1092.
49. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
50. Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
51. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 2003;349:1793-1802.
52. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of National Cancer Institute 2007;99:1845-53.
53. Goss P, Ingle J, Martino S, Robert N, Muss H, Piccart M, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA-17. Journal of National Cancer Institute 2005;97:1262-71.
54. Dowsett M. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen and progesterone receptor status. Breast Cancer Research and Treatment 2003;82:S7.
55. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.[see comment]. Journal of Clinical Oncology 2001;19(18):3808-16.
56. Howell A, Robertson J, Abram P, Lichinitser M, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology 2004 22:1605-13.
57. Hui R, Ball J, Macmillan R, et al. EMSI gene expression in primary breast cancer: relationship cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998;17:1053-1059.
58. Hui R, Cornish A, McClelland R, et al. Cyclin DI and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 1996;2:923-928.
59. Kenny F, Hui R, Musgrove E, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 1999;5:2069-2076.
60. Robertson J, Gutteridge E, Cheung K, Owers R, Koehler M, Hamilton L, et al. Gefitinib ('Iressa', ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor-positive and oestrogen receptor-negative breast cancer: results from a Phase II study. Journal of Clinical Oncology Program and Proceedings of ASCO Annual Meeting 2003.
61. Mackey J, et al. Trastuzumab prolongs progression-free survival in hormonedependent and HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment 2006;100 (Suppl):S5-6.
62. Cheung K, Wong A, Parker H, Li V, Winterbottom L, Morgan D, et al. Pathological features of primary breast cancer in the elderly based on needle core biopsies - A large series from a single centre. Critical Reviews in Oncology-Hematology 2008.
63. Ying M, Agrawal A, Winterbottom L, Morgan D, Ellis I, Cheung K. Anastrozole versus tamoxifen as primary endocrine therapy for early operable primary breast cancer in the elderly. Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I 2007;25:18S:11025.
64. Viale G, Regan M, Maiorano E, Mastropasqua M, Golouh R, Perin T, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology 2008;26:1404-10.
65. Stearns V, Johnson M, Rae J, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of National Cancer Institute 2003;95:1758-64.
66. Punglia R, Burstein H, Winer E, Weeks J. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. Journal of National Cancer Institute 2008;100:642-8.
67. Goetz M, Knox S, Suman V, Rae J, Safgren S, Ames M, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment 2007;101:113-21.